Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.52 |
| ▸ | FAAH | O00519 | 3/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | CDC25A | P30304 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.41 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6232792 | 1.00 | MGLL (0.52) | MGLLPTGS1PTGS2FAAHCES1 | |
| SCHEMBL11499891 | 0.98 | MGLL (0.48) | MGLLPTGS1PTGS2FAAHCES1 | |
| SCHEMBL2728279 | 0.92 | HPGD (0.49) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL1101255 | 0.89 | MGLL (0.53) | MGLLPTGS1PTGS2FAAHCES1 | |
| SCHEMBL11499124 | 0.88 | MGLL (0.50) | MGLLPTGS1PTGS2FAAHCES1 | |
| SCHEMBL2728584 | 0.83 | KMT2A (0.44) | ALDH1A1KDM4EMAPTHPGDNPSR1 | |
| SCHEMBL1101454 | 0.80 | ALDH1A1 (0.47) | MGLLPTGS1PTGS2FAAHCES1 | |
| SCHEMBL11787515 | 0.78 | MGLL (0.46) | MGLLPTGS1PTGS2FAAHCES1 | |
| SCHEMBL7153652 | 0.75 | MGLL (0.60) | MGLLPTGS1PTGS2FAAHCES1 | |
| SCHEMBL11477209 | 0.74 | MEN1 (0.49) | MGLLPTGS1PTGS2FAAHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0194226-B1 | A PHARMACEUTICAL COMPOSITION CONTAINING AN IMIDAZOLIDINETRIONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1990-02-07 | — | — | EP | claimed |
| EP-1243261-B1 | Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2005-04-27 | — | — | EP | disclosed |
| EP-1018339-B1 | Use of hydantoin derivatives for the preparation of a medicament for the treatment of intractable vasculitis. | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2003-05-02 | — | — | EP | disclosed |
| US-20020147228-A1 | AGENT FOR HYPOALBUMINAEMIA | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2002-10-10 | — | — | US | disclosed |
| EP-1243261-A1 | Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2002-09-25 | — | — | EP | disclosed |
| US-6451831-B1 | TREATMENT WITH HYDANTOIN DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2002-09-17 | — | — | US | disclosed |
| US-6251929-B1 | ADMINISTERING TO A PATIENT A HYDANTOIN DERIVATIVES AND SALTS AS THERAPEUTIC AND PREVENTIVE AGENTS FOR INTRACTABLE VASCULITIS SUCH AS MALIGNANT RHEUMATOID ARTHRITIS(MRA), PERIARTERITIS NODOSA, WEGENER'S GRANULOMATOSIS ETC. | NIPPON ZOKI PHARMACEUTICALS CO., LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-0780125-B1 | Use of hydantoin derivatives for the preparation of a medicament for the treatment of dieases associated with the presence of active oxygen and free radicals | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2001-04-18 | — | — | EP | disclosed |
| US-6197806-B1 | USING A HYDANTOIN DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-1018339-A1 | Therapeutic agent for intractable vasculitis | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-12 | — | — | EP | disclosed |
| EP-0780125-A2 | Pharmaceutical composition containing a hydantoin derivative and use of said derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-25 | — | — | EP | disclosed |
| EP-0194226-B1 | A PHARMACEUTICAL COMPOSITION CONTAINING AN IMIDAZOLIDINETRIONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1990-02-07 | — | — | EP | disclosed |
| US-4683240-A | HYPOGLYCEMIC, HYPOUPIDEMIC | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1987-07-28 | — | — | US | disclosed |
| EP-0194226-A1 | A pharmaceutical composition containing an imidazolidinetrione derivative or pharmaceutically acceptable salt thereof | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1986-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147228-A1 | AGENT FOR HYPOALBUMINAEMIA | ALB, TTR, SERPINA6 | MGLL 1935/4885PTGS1 791/4885PTGS2 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.